Contents

Volume 46, Number 1, July 1998

Review

1 Sorivudine and 5-fluorouracil; a clinically significant drug-drug interaction due to inhibition of dihydropyrimidine dehydrogenase: *R. B. Diasio*

Pharmacokinetics

5 Pharmacokinetics of recombinant human interleukin-2 in advanced renal cell carcinoma patients following subcutaneous application: *G. I. Kirchner, A. Franzke, J. Buer, W. Beil, M. Probst-Kepper, F. Wittke, K. Övermann, S. Lassmann, R. Hoffmann, H. Kirchner, A. Ganser & J. Atzpodien*

11 Pharmacokinetic analysis of subcutaneous erythropoietin administration with nonlinear mixed effect model including endogenous production: *N. Hayashi, H. Kinoshita, E. Yukawa & S. Higuchi*

21 Single dose pharmacokinetics of lamivudine in subjects with impaired renal function and the effect of haemodialysis: *M. A. Johnson, G. A. Verpooten, M. J. Daniel, R. Plumb, J. Moss, D. Van Caesbroeck & M. E. De Broe*

29 Topical penetration of commercial salicylate esters and salts using isolated human skin and clinical microdialysis studies: *S. E. Cross, C. Anderson & M. S. Roberts*

Inhaled drugs

37 Pulmonary administration of aerosolised fentanyl: pharmacokinetic analysis of systemic delivery: *L. E. Mather, L. E. Mather, A. Woodhouse, M. E. Ward, S. J. Farr, R. A. Rubsamen & L. G. Eltherington*

45 Early lung absorption profile of non-CFC salbutamol via small and large volume plastic spacer devices: *B. J. Lipworth & D. J. Clark*

Drug interactions

49 Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin: *K. T. Kivistö, T. Kantola & P. J. Neuvonen*

55 Involvement of CYP1A2 in mexiletine metabolism: *M. Nakajima, K. Kobayashi, N. Shimada, S. Tokudome, T. Yamamoto & Y. Kuroiwa*

Pharmacovigilance

63 Perindopril postmarketing surveillance: a twelve-month study in 47 351 hypertensive patients: *C. Speirs, F. Wagniart & L. Poggi*

71 Risk factors for mortality in users of ibopamine: *J. Feenstra, B. A. in't Veld, P. D. van der Linden, D. E. Grobbee & B. H. Ch. Stricker*

Short reports

79 Adverse effects of a single dose of (+)-sotalol in patients with mild stable asthma: *G. Devereux, K. Fishwick, T. C. Aiken, S. J. Bourke & D. J. Hendrick*

83 Effect of food and gender on the pharmacokinetics of tucaresol in healthy volunteers: *R. W. Peck, R. Wootton, R. Wiggs, G. Layton & J. Posner*

Letters to Editors

87 Variability in the frequency of cytochrome P450-2D6 (CYP2D6) deficiency: *K. Mörike, H.-P. Platten, G. Mikus & U. Klotz*

88 Levodopa monitoring by retrodialysis *D. Deleu*

88 Risk of gastrointestinal haemorrhage with calcium antagonists: *K. Desbocuf, M. Lapeyre-Mestre & J.-L. Montastruc*

Book Review

91 Drugs and human lactation: *M. Orme*

91 Medical Pharmacology at a Glance: *J. K. Aronson*

Volume 46, Number 2, August 1998

Reviews

93 Therapeutic drug monitoring beyond 2000: *G. M. Shenfield*

95 Best practice in therapeutic drug monitoring: *A. S. Gross*

101 Grapefruit juice–drug interactions: *D. G. Bailey, J. Malcolm, O. Arnold & J. D. Spence*

Pharmacokinetics and drug disposition

111 Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers: *D. Ouellet, A. Hsu, J. Qian, C. S. Locke, C. J. Eason, J. H. Cavanaugh, J. M. Leonard & G. R. Granneman*

117 Population pharmacokinetics of ondansetron: a covariate analysis: *D. P. de Alwis, L. Aarons & J. L. Palmer*

Pharmacodynamics

127 Lacidipine: effects on vascular pressor responses throughout the dosage interval in normotensive subjects: *S. Ueda, R. Donnelly, V. Panfilov, A. D. Morris & H. L. Elliott*

133 Gastrointestinal tolerability of meloxicam and piroxicam: a double-blind placebo-controlled study: *G. R. Lipscomb, N. Wallis, G. Armstrong & W. D. W. Rees*

139 The effect of aspirin on thrombin stimulated platelet adhesion receptor expression and the role of neutrophils: *M. L. Taylor, M. K. Ilton, N. L. A. Misso, D. N. Watkins, J. Hung & P. J. Thompson*

Clinical trials

147 Bias in reporting clinical trials: A. H. *Bardy*

Pharmacogenetics

151 Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects: S. A. *Ridge, J. Sludden, O. Brown, L. Robertson, X. Wei, A. Sapone, P. M. Fernandez-Salguero, F. J. Gonzalez, P. Vreken, A. B. P. van Kuilenburg, A. H. van Gennip & H. L. McLeod*

Therapeutics

157 A new regimen for start warfarin therapy in out-patients: A. *Oates, P. R. Jackson, C. A. Austin & K. S. Channer*

163 Constant rate infusion of vancomycin in premature neonates: a new dosage schedule: *F. Pawlotsky, A. Thomas, M. F. Kergueris, T. Debillon & J. C. Roze*

Short reports

169 Start of therapy with the angiotensin II antagonist losartan after immediate switch from pretreatment with an ACE inhibitor: *J. Scholze & M. Stapff*

173 Mesalazine release from a pH dependent formulation: effects of omeprazole and lactulose co-administration: F. N. Hussain, R. A. Ajjan, M. Moustafa, N. W. Weir & *S. A. Riley*

176 Plasma hydroxy metronidazole/metronidazole ratio in anti-HCV carriers with and without apparent liver disease: *C. M. F. da Silva, F. L. David, M. N. Muscará, S. S. Sousa, J. G. P. Ferraz, G. De Nucci, N. C. Polimeno & J. Pedrazzoli*

181 *Possible association between ocular chloramphenicol and aplastic anaemia — the absolute risk is very low. J.-R. Laporte, X. Vidal, E. Ballarín & L. Ibáñez*

Volume 46, Number 3, September 1998

Reviews

185 Therapeutic drug monitoring — antiepileptic drugs: *M.J. Eadie*

195 Prescription-event monitoring — recent progress and future horizons: *R.D. Mann*

Drug delivery

203 Midazolam pharmacokinetics following intravenous and buccal administration: *R. Schwagmeier, S. Alincic & H.W. Striebel*

207 The gastrointestinal passage and release of beclomethasone dipropionate from oral delivery systems in ileostomy volunteers: *J. Burggraaf, A.D. van Haarst, P. Fockens, H.C. Schoemaker, W.J.J. Krauwinkel & A.F. Cohen*

Drug metabolism and disposition

215 Chloroquine modulation of specific metabolizing enzymes activities: investigation with selective five drug cocktail: *A. Adedoyin, R.F. Frye, K. Mauro & R.A. Branch*

221 Caffeine based measures of CYP1A2 activity correlate with oral clearance of tacrine in patients with Alzheimer's disease: *R.J. Fontana, T.M. deVries, T.F. Woolf, M.J. Knapp, A.S. Brown, L.S. Kaminsky, B.K. Tang, N.L. Foster, R.R. Brown & P.B. Watkins*

Population pharmacokinetics

229 Population pharmacokinetics of gentamicin in patients with cancer: *M.C. Rosario, A.H. Thomson, D.I. Jodrell, C.A. Sharp & H.L. Elliott*

237 Paracetamol plasma and cerebrospinal fluid pharmacokinetics in children: *B.J. Anderson, N.H.G. Holford, G.A. Woollard & P.L.S. Chan*

Pharmacodynamics

245 A comparison of the cardiovascular effects of levobupivacaine and *rac*-bupivacaine following intravenous administration to healthy volunteers: *H. Bardsley, R. Gristwood, H. Baker, N. Watson & W. Nimmo*

Pharmacovigilance

251 Terfenadine and risk of acute liver disease: *M.W. Myers & H. Jick*

255 Constipation as an adverse effect of drug use in nursing home patients: an overestimated risk: *K.N. van Dijk, C.S. de Vries, P.B. van den Berg, A.M. Dijkema, J.R.B.J. Brouwers & L.T.W. de Jong-van den Berg*

Short reports

263 Nitric oxide: an important role in the maintenance of systemic and pulmonary vascular tone in man: *D.G. Kiely, A.F.C. Lee, A.D. Struthers & B.J. Lipworth*

267 Effect of age and gender on the pharmacokinetics of eprosartan: *D.M. Tenero, D.E. Martin, A.K. Miller, B. Ilson, S.C. Boike, N. Zariffa & D.K. Jorkasky*

Letters to Editors

271 Evidence for a pharmacokinetic interaction between itraconazole and tacrolimus in organ transplant patients: *E.M. Billaud, R. Guillemain, F. Tacco & P. Chevalier*

272 Norfloxacin exhibits negligible serum concentrations after repeated conjunctival instillation in children: *F. Drago, C. La Manna, V. Marino, A. Marino, I. Emmi & A. Reibaldi*

Book review

275 A manual of adverse drug interactions: *J.C. Mucklow*

277 **Proceedings of the British Pharmacological Society Meeting, Chester, 22–24 April 1998**

Volume 46, Number 4, October 1998

Reviews

307 Therapeutic drug monitoring: antiarrhythmic drugs: *T. J. Campbell & K. M. Williams*

321 Expanding clinical applications of population pharmacodynamic modelling: *C. Minto & T. Schnider*

335 Recent advances in the management of unstable angina and non-Q-wave myocardial infarction: *R. P. Steeds & K. S. Channer*

Case study

343 Case studies in therapeutics: warfarin resistance and inefficacy in a man with recurrent thromboembolism, and anticoagulant-associated priapism: *P. A. Routledge, H. G. M. Shetty, J. P. White & P. Collins*

Meeting reports

347 Training and development conferences for members of research ethics committees assessing clinical pharmacology studies: *K. Doyle & R. Tiner*

351 Drugs and the liver, 21 April 1998, Chester, UK

360 Heart failure, 23 April 1998, Chester, UK

Pharmacokinetics

363 Single dose and steady state pharmacokinetics of temocapril and temocaprilat in young and elderly hypertensive patients: *K. Püchler, B. Sierakowski & I. Roots*

369 The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis: *C. Godfrey, K. Sweeney, K. Miller, R. Hamilton & J. Kremer*

Drug interaction

377 Ferrous sulfate interacts with captopril: *J. P. Schaefer, Y. Tam, B. B. Hasinoff, S. Tawfik, Y. Peng, L. Reimche & N. R. C. Campbell*

Pharmacokinetics and pharmacodynamics

383 Pharmacokinetic-pharmacodynamic model relating zabiciprilat plasma concentrations to brachial and femoral haemodynamic effects in normotensive volunteers: *E. Bellissant & J.-F. Giudicelli*

Paediatric pharmacodynamics

395 An approach for dose finding of drugs in infants: sedation by midazolam studied using the continual reassessment method: *E. Fabre, S. Chevret, J.-F. Piechaud, E. Rey, F. Vauzelle-Kervroedan, P. D'Athis, G. Olive & G. Pons*

Pharmacoepidemiology

403 Prescription patterns of diuretics in Dutch community-dwelling elderly patients: *D. J. W. van Kraaij, R. W. M. M. Jansen, J. J. de Gier, F. W. J. Gribnau & W. H. L. Hoefnagels*

Short report

409 Compliance with restrictions on the subsidized use of proton pump inhibitors in Australia: *P. McManus, J. Marley, D. J. Birkett & J. Lindner*

Book reviews

413 The design and analysis of sequential clinical trials: *G. D. Murray*

413 Drug therapy in old age: *D. J. Stott*

Volume 46, Number 5, November 1998

Review

415 Clinical pharmacy in primary care: *G. M. Hawksworth & H. Chrystyn*

Case study

421 Heart failure in thyrotoxicosis, an approach to management: *R. P. Choudhury & J. MacDermot*

Pharmacokinetics

425 Direct assessment of peripheral pharmacokinetics in humans: comparison between cantharides blister fluid sampling, *in vivo* microdialysis and saliva sampling: *M. Brunner, A. Schmiedberger, R. Schmid, D. Jäger, E. Piegler, H. G. Eichler & M. Müller*

433 The absolute bioavailability and effect of food on the pharmacokinetics of zolmitriptan in healthy volunteers: *E. J. Seaber, R. W. Peck, D. A. Smith, J. Allanson, N. R. Hefting, J. J. van Lier, F. A. E. Sollie, J. Wemer & J. H. G. Jonkman*

441 Stereoselective steady state disposition and action of propafenone in Chinese subjects: *G. Li, P.-L. Gong, J. Qiu, F.-D. Zeng & U. Klotz*

447 Relationships among liver and kidney volumes, lean body mass and drug clearance: *S. Nawaratne, J. E. Brien, E. Seeman, R. Fabiny, J. Zalcberg, W. Cosolo, P. Angus & D. J. Morgan*

453 Pharmacokinetics of clozapine and its metabolites in psychiatric patients: plasma protein binding and renal clearance: *G. Schaber, I. Stevens, H. J. Gaertner, K. Dietz & U. Breyer-Pfaff*

Pharmacodynamics

461 Predicting the time course of haemoglobin in children treated with erythropoietin for renal anaemia: *R. E. Port, R. W. Ding, T. Fies & K. Schärer*

467 Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertensive patients: *R. Fogari, A. Zoppi, L. Corradi, P. Lazzari, A. Mugellini & P. Lusardi*

473 Effects of acipimox on haemorpheology and plasma lipoproteins in patients with mixed hyperlipoproteinaemia: *C. Otto, K. G. Parhofer, M. M. Ritter, W. O. Richter & P. Schwandt*

Pharmacokinetics/pharmacodynamics

479 The influence of drug input rate on the development of tolerance to frusemide: *M. Wakelkamp, G. Alván, H. Scheinin & J. Gabrielsson*

489 L-arginine-induced vasodilation in healthy humans: pharmacokinetic-pharmacodynamic relationship: *S. M. Bode-Böger, R. H. Böger, A. Galland, D. Tsikas & J. C. Frölich*

Drug metabolism

499 Relationship between proguanil metabolic ratio and *CYP2C19* genotype in a Caucasian population: *J. M. Hoskins, G. M. Shenfield & A. S. Gross*

Adverse drug reactions

505 Age and sex distribution of suspected adverse drug reactions to newly marketed drugs in general practice in England: analysis of 48 cohort studies: *R. M. Martin, P. N. Biswas, S. N. Freemantle, G. L. Pearce & R. D. Mann*

Short Report

513 Paracetamol metabolism in patients with ulcerative colitis: *K. V. Haderslev, J. Sonne, H. E. Poulsen & S. Loft*

Letters to Editors

517 Can endothelial function be assessed *in vivo* by measuring acetylcholine induced changes in nitrate in the forearm in man?: *R. Butler, A. D. Morris, A. Leone & A. D. Struthers*

518 Hyperlipidaemia following treatment with protease inhibitors in patients with HIV-1 infection: *D. R. Churchill, A. S. Pym, A. G. Babiker, D. J. Back & J. N. Weber*

Book review

520 Drug development for women: *G. M. Shenfield*

Volume 46, Number 6, December 1998

Reviews

521 Safety assessment of peroxide antimalarials: clinical and chemical perspectives: *B. K. Park, P. M. O'Neill, J. L. Maggs & M. Pirmohamed*

531 Prescribing for the elderly patient: why do we need to exercise caution?: *S. G. Hughes*

Drug metabolism

535 The lignocaine metabolite (MEGX) liver function test and P-450 induction in humans: *C. Reichel, T. Skodra, A. Nacke, U. Spengler & T. Sauerbruch*

Renal elimination

541 Influence of urine pH and urinary flow on the renal excretion of memantine: *S. Freudenthaler, I. Meineke, K.-H. Schreeb, E. Boakye, U. Gundert-Remy & C. H. Gleiter*

Therapeutic drug monitoring

547 Lamotrigine and therapeutic drug monitoring: retrospective survey following the introduction of a routine service: *R. G. Morris, A. B. Black, A. L. Harris, A. B. Batty & B. C. Sallustio*

Pharmacokinetics/pharmacodynamics

553 Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients: *F. Ezzet, R. Mull & J. Karbwang*

563 Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions: *S. Khakoo, P. Glue, L. Grellier, B. Wells, A. Bell, C. Dash, I. Murray-Lyon, D. Lypnyj, B. Flannery, K. Walters & G. M. Dusheiko*

Vascular pharmacodynamics

571 Frusemide inhibits angiotensin II-induced contraction on human vascular smooth muscle: *F. Stanke, P. Devillier, D. Bréant, O. Chavanon, C. Sessa, G. Bricca & G. Bessard*

577 Comparison of the vasoconstrictor effects of rizatriptan and sumatriptan in human isolated cranial arteries: immunohistological demonstration of the involvement of 5-HT_{1B}-receptors: *J. Longmore, Z. Razzaque, D. Shaw, A. P. Davenport, J. Maguire, J. D. Pickard, W. N. Schofield & R. G. Hill*

583 Endogenous angiotensin II and baroreceptor dysfunction: a comparative study of losartan and enalapril in man: *K. M. Yee & A. D. Struthers*

589 Impaired pressor sensitivity to noradrenaline in septic shock patients with and without impaired adrenal function reserve: *D. Annane, E. Bellissant, V. Sebille, O. Lesieur, B. Mathieu, J. C. Raphael & P. Gajdos*

599 Attenuation by ACE inhibitor drugs of α-adrenoceptor sensitivity in human vessels: possible differences related to drug lipophilicity: *M. Kimura, K. Umemura, K. Kosuge, M. Nishimoto, K. Ohashi & M. Nakashima*

Short reports

605 Determination of inulin clearance by bolus intravenous injection in healthy subjects and ascitic patients: equivalence of systemic and renal clearances as glomerular filtration markers: *R. Orlando, M. Floreani, R. Padrini & P. Palatini*

611 The effects of age and gender on the pharmacokinetics of irbesartan: *N. N. Vachharajani, W. C. Shyu, R. A. Smith & D. S. Greene*

Book reviews

615 The paediatric lung: *A. Smyth*

615 Streetwise drugwise: *K. O'Kane*

616 Sample size tables for clinical studies: *L. Murray*

617P Proceedings of the Dutch Pharmacology Society Meeting, 3 April 1998

633 Indexes to Volume 46